Global Immunoglobulin Products Market

Immunoglobulin Products Comprehensive Study by Type (IgA, IgG, IgM, IgD, IgE), Application (Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Hypogammaglobulinemia, Immunodeficiency Disease, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Multifocal Motor Neuropathy, Myasthenia Gravis, Specific Antibody Deficiency, Others), Mode of Delivery (Subcutaneous (16.5% Concentration, 20% Concentration and Other), Intravenous (5% Concentration, 10% Concentration and Other)), End User (Drugstore, Hospital, Others) Players and Region - Global Market Outlook to 2030

Immunoglobulin Products Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Immunoglobulin Products Market Scope?
Immunoglobulin’s also called as antibodies are large Y-shaped protein produced by B-cell. These are the glycoprotein molecule produced by plasma cells in response to entry of foreign entity including bacteria and viruses in the body. Production of antibodies is an important function of immune system. The increasing incidences of autoimmune diseases such as multiple sclerosis, primary humoral immunodeficiency, immune thrombocytopenia purpura (ITP), and autoimmune hemolytic anemia and increasing geriatric population worldwide, and rising hemophilic patient numbers are driving the growth of immunoglobulin products market globally

Influencing Trend:
Emergence of Advanced Technologies, and Enhanced Purification Techniques

Market Growth Drivers:
Surge in Prevalence Various Diseases Including Chronic Inflammatory Demyelinating Polyneuropathy and Others and Increasing Geriatric Population & Number of Hemophilic Patients Worldwide

Challenges:
High Risk of Side Effects

Restraints:
Stringent Government Regulations toward Immunoglobulin Products and high Treatment Cost

Opportunities:
The Increasing Growth of Immunoglobulin Products in Emerging Economies and Surging Awareness Regarding Primary Immunodeficiency Diseases Treatment Across the Globe

The Immunoglobulin Products market study is being classified by Type (IgA, IgG, IgM, IgD and IgE), by Application and major geographies with country level break-up.

Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Immunoglobulin Products market throughout the predicted period.

Takeda Pharmaceutical Company (Japan), CSL Limited (Australia), Grifols (Spain), Biotest Pharmaceuticals Corporation (United States), Kedrion (Italy), Octapharma AG (Switzerland), Abeona Therapeutics (United States), ADMA Biologics (United States), Emergent Biosolutions. (United States), Anthera Pharmaceuticals (United States) and Beijing Tiantan Biological Products (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Bharat Serums and Vaccines (India), Emergent Biosolutions (United States), Gliknik (United States), Hansamedical (Sweden), Hualan Biological Engineering (China), Immunomedics (United States) and Innate Pharma (France).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Immunoglobulin Products market by Type, Application and Region.

On the basis of geography, the market of Immunoglobulin Products has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their Development Strategies

In December 2019 Grifols a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin (IG) innovation, XEMBIFY® (immune globulin subcutaneous human-klhw), the company’s first 20% subcutaneous immunoglobulin therapy for the treatment of patients 2 years of age and older with primary immunodeficiency (PI).
The European Medicines Agency's scientific guidelines on the clinical evaluation of blood products help medicine developers prepare marketing authorisation applications for human medicines., and Canadian Blood Services and National Advisory Committee on Blood and Blood Products of Canada provide practice guidelines on the usage of IVIg products in hematological diseases.

Key Target Audience
Immunoglobulin Products Manufacturers, Immunoglobulin Products Distributors/Suppliers, Government Organizations, Research Institutes, End User and Others

Immunoglobulin Products Market Study: Important Years
AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Immunoglobulin Products Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Immunoglobulin Products industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • IgA
  • IgG
  • IgM
  • IgD
  • IgE
By Application
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Guillain-Barre Syndrome
  • Hypogammaglobulinemia
  • Immunodeficiency Disease
  • Idiopathic Thrombocytopenic Purpura
  • Inflammatory Myopathies
  • Multifocal Motor Neuropathy
  • Myasthenia Gravis
  • Specific Antibody Deficiency
  • Others
By Mode of Delivery
  • Subcutaneous (16.5% Concentration, 20% Concentration and Other)
  • Intravenous (5% Concentration, 10% Concentration and Other)

By End User
  • Drugstore
  • Hospital
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Surge in Prevalence Various Diseases Including Chronic Inflammatory Demyelinating Polyneuropathy and Others
      • 3.2.2. Increasing Geriatric Population & Number of Hemophilic Patients Worldwide
    • 3.3. Market Challenges
      • 3.3.1. High Risk of Side Effects
    • 3.4. Market Trends
      • 3.4.1. Emergence of Advanced Technologies, and Enhanced Purification Techniques
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Immunoglobulin Products, by Type, Application, Mode of Delivery, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Immunoglobulin Products (Value)
      • 5.2.1. Global Immunoglobulin Products by: Type (Value)
        • 5.2.1.1. IgA
        • 5.2.1.2. IgG
        • 5.2.1.3. IgM
        • 5.2.1.4. IgD
        • 5.2.1.5. IgE
      • 5.2.2. Global Immunoglobulin Products by: Application (Value)
        • 5.2.2.1. Chronic Inflammatory Demyelinating Polyneuropathy
        • 5.2.2.2. Guillain-Barre Syndrome
        • 5.2.2.3. Hypogammaglobulinemia
        • 5.2.2.4. Immunodeficiency Disease
        • 5.2.2.5. Idiopathic Thrombocytopenic Purpura
        • 5.2.2.6. Inflammatory Myopathies
        • 5.2.2.7. Multifocal Motor Neuropathy
        • 5.2.2.8. Myasthenia Gravis
        • 5.2.2.9. Specific Antibody Deficiency
        • 5.2.2.10. Others
      • 5.2.3. Global Immunoglobulin Products by: Mode of Delivery (Value)
        • 5.2.3.1. Subcutaneous (16.5% Concentration, 20% Concentration and Other)
        • 5.2.3.2. Intravenous (5% Concentration, 10% Concentration and Other)
      • 5.2.4. Global Immunoglobulin Products by: End User (Value)
        • 5.2.4.1. Drugstore
        • 5.2.4.2. Hospital
        • 5.2.4.3. Others
      • 5.2.5. Global Immunoglobulin Products Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Immunoglobulin Products: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Takeda Pharmaceutical Company (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CSL Limited (Australia)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Grifols (Spain)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biotest Pharmaceuticals Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Kedrion (Italy)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Octapharma AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abeona Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. ADMA Biologics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Emergent Biosolutions. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Anthera Pharmaceuticals (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Beijing Tiantan Biological Products (China)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Immunoglobulin Products Sale, by Type, Application, Mode of Delivery, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Immunoglobulin Products (Value)
      • 7.2.1. Global Immunoglobulin Products by: Type (Value)
        • 7.2.1.1. IgA
        • 7.2.1.2. IgG
        • 7.2.1.3. IgM
        • 7.2.1.4. IgD
        • 7.2.1.5. IgE
      • 7.2.2. Global Immunoglobulin Products by: Application (Value)
        • 7.2.2.1. Chronic Inflammatory Demyelinating Polyneuropathy
        • 7.2.2.2. Guillain-Barre Syndrome
        • 7.2.2.3. Hypogammaglobulinemia
        • 7.2.2.4. Immunodeficiency Disease
        • 7.2.2.5. Idiopathic Thrombocytopenic Purpura
        • 7.2.2.6. Inflammatory Myopathies
        • 7.2.2.7. Multifocal Motor Neuropathy
        • 7.2.2.8. Myasthenia Gravis
        • 7.2.2.9. Specific Antibody Deficiency
        • 7.2.2.10. Others
      • 7.2.3. Global Immunoglobulin Products by: Mode of Delivery (Value)
        • 7.2.3.1. Subcutaneous (16.5% Concentration, 20% Concentration and Other)
        • 7.2.3.2. Intravenous (5% Concentration, 10% Concentration and Other)
      • 7.2.4. Global Immunoglobulin Products by: End User (Value)
        • 7.2.4.1. Drugstore
        • 7.2.4.2. Hospital
        • 7.2.4.3. Others
      • 7.2.5. Global Immunoglobulin Products Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Immunoglobulin Products: by Type(USD Million)
  • Table 2. Immunoglobulin Products IgA , by Region USD Million (2018-2023)
  • Table 3. Immunoglobulin Products IgG , by Region USD Million (2018-2023)
  • Table 4. Immunoglobulin Products IgM , by Region USD Million (2018-2023)
  • Table 5. Immunoglobulin Products IgD , by Region USD Million (2018-2023)
  • Table 6. Immunoglobulin Products IgE , by Region USD Million (2018-2023)
  • Table 7. Immunoglobulin Products: by Application(USD Million)
  • Table 8. Immunoglobulin Products Chronic Inflammatory Demyelinating Polyneuropathy , by Region USD Million (2018-2023)
  • Table 9. Immunoglobulin Products Guillain-Barre Syndrome , by Region USD Million (2018-2023)
  • Table 10. Immunoglobulin Products Hypogammaglobulinemia , by Region USD Million (2018-2023)
  • Table 11. Immunoglobulin Products Immunodeficiency Disease , by Region USD Million (2018-2023)
  • Table 12. Immunoglobulin Products Idiopathic Thrombocytopenic Purpura , by Region USD Million (2018-2023)
  • Table 13. Immunoglobulin Products Inflammatory Myopathies , by Region USD Million (2018-2023)
  • Table 14. Immunoglobulin Products Multifocal Motor Neuropathy , by Region USD Million (2018-2023)
  • Table 15. Immunoglobulin Products Myasthenia Gravis , by Region USD Million (2018-2023)
  • Table 16. Immunoglobulin Products Specific Antibody Deficiency , by Region USD Million (2018-2023)
  • Table 17. Immunoglobulin Products Others , by Region USD Million (2018-2023)
  • Table 18. Immunoglobulin Products: by Mode of Delivery(USD Million)
  • Table 19. Immunoglobulin Products Subcutaneous (16.5% Concentration, 20% Concentration and Other) , by Region USD Million (2018-2023)
  • Table 20. Immunoglobulin Products Intravenous (5% Concentration, 10% Concentration and Other) , by Region USD Million (2018-2023)
  • Table 21. Immunoglobulin Products: by End User(USD Million)
  • Table 22. Immunoglobulin Products Drugstore , by Region USD Million (2018-2023)
  • Table 23. Immunoglobulin Products Hospital , by Region USD Million (2018-2023)
  • Table 24. Immunoglobulin Products Others , by Region USD Million (2018-2023)
  • Table 25. South America Immunoglobulin Products, by Country USD Million (2018-2023)
  • Table 26. South America Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 27. South America Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 28. South America Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 29. South America Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 30. Brazil Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 31. Brazil Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 32. Brazil Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 33. Brazil Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 34. Argentina Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 35. Argentina Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 36. Argentina Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 37. Argentina Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 38. Rest of South America Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 39. Rest of South America Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 40. Rest of South America Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 41. Rest of South America Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 42. Asia Pacific Immunoglobulin Products, by Country USD Million (2018-2023)
  • Table 43. Asia Pacific Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 44. Asia Pacific Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 45. Asia Pacific Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 46. Asia Pacific Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 47. China Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 48. China Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 49. China Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 50. China Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 51. Japan Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 52. Japan Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 53. Japan Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 54. Japan Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 55. India Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 56. India Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 57. India Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 58. India Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 59. South Korea Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 60. South Korea Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 61. South Korea Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 62. South Korea Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 63. Taiwan Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 64. Taiwan Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 65. Taiwan Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 66. Taiwan Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 67. Australia Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 68. Australia Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 69. Australia Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 70. Australia Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 73. Rest of Asia-Pacific Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 74. Rest of Asia-Pacific Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 75. Europe Immunoglobulin Products, by Country USD Million (2018-2023)
  • Table 76. Europe Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 77. Europe Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 78. Europe Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 79. Europe Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 80. Germany Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 81. Germany Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 82. Germany Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 83. Germany Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 84. France Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 85. France Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 86. France Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 87. France Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 88. Italy Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 89. Italy Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 90. Italy Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 91. Italy Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 92. United Kingdom Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 93. United Kingdom Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 94. United Kingdom Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 95. United Kingdom Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 96. Netherlands Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 97. Netherlands Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 98. Netherlands Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 99. Netherlands Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 100. Rest of Europe Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 101. Rest of Europe Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 102. Rest of Europe Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 103. Rest of Europe Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 104. MEA Immunoglobulin Products, by Country USD Million (2018-2023)
  • Table 105. MEA Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 106. MEA Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 107. MEA Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 108. MEA Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 109. Middle East Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 110. Middle East Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 111. Middle East Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 112. Middle East Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 113. Africa Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 114. Africa Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 115. Africa Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 116. Africa Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 117. North America Immunoglobulin Products, by Country USD Million (2018-2023)
  • Table 118. North America Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 119. North America Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 120. North America Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 121. North America Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 122. United States Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 123. United States Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 124. United States Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 125. United States Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 126. Canada Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 127. Canada Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 128. Canada Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 129. Canada Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 130. Mexico Immunoglobulin Products, by Type USD Million (2018-2023)
  • Table 131. Mexico Immunoglobulin Products, by Application USD Million (2018-2023)
  • Table 132. Mexico Immunoglobulin Products, by Mode of Delivery USD Million (2018-2023)
  • Table 133. Mexico Immunoglobulin Products, by End User USD Million (2018-2023)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Immunoglobulin Products: by Type(USD Million)
  • Table 146. Immunoglobulin Products IgA , by Region USD Million (2025-2030)
  • Table 147. Immunoglobulin Products IgG , by Region USD Million (2025-2030)
  • Table 148. Immunoglobulin Products IgM , by Region USD Million (2025-2030)
  • Table 149. Immunoglobulin Products IgD , by Region USD Million (2025-2030)
  • Table 150. Immunoglobulin Products IgE , by Region USD Million (2025-2030)
  • Table 151. Immunoglobulin Products: by Application(USD Million)
  • Table 152. Immunoglobulin Products Chronic Inflammatory Demyelinating Polyneuropathy , by Region USD Million (2025-2030)
  • Table 153. Immunoglobulin Products Guillain-Barre Syndrome , by Region USD Million (2025-2030)
  • Table 154. Immunoglobulin Products Hypogammaglobulinemia , by Region USD Million (2025-2030)
  • Table 155. Immunoglobulin Products Immunodeficiency Disease , by Region USD Million (2025-2030)
  • Table 156. Immunoglobulin Products Idiopathic Thrombocytopenic Purpura , by Region USD Million (2025-2030)
  • Table 157. Immunoglobulin Products Inflammatory Myopathies , by Region USD Million (2025-2030)
  • Table 158. Immunoglobulin Products Multifocal Motor Neuropathy , by Region USD Million (2025-2030)
  • Table 159. Immunoglobulin Products Myasthenia Gravis , by Region USD Million (2025-2030)
  • Table 160. Immunoglobulin Products Specific Antibody Deficiency , by Region USD Million (2025-2030)
  • Table 161. Immunoglobulin Products Others , by Region USD Million (2025-2030)
  • Table 162. Immunoglobulin Products: by Mode of Delivery(USD Million)
  • Table 163. Immunoglobulin Products Subcutaneous (16.5% Concentration, 20% Concentration and Other) , by Region USD Million (2025-2030)
  • Table 164. Immunoglobulin Products Intravenous (5% Concentration, 10% Concentration and Other) , by Region USD Million (2025-2030)
  • Table 165. Immunoglobulin Products: by End User(USD Million)
  • Table 166. Immunoglobulin Products Drugstore , by Region USD Million (2025-2030)
  • Table 167. Immunoglobulin Products Hospital , by Region USD Million (2025-2030)
  • Table 168. Immunoglobulin Products Others , by Region USD Million (2025-2030)
  • Table 169. South America Immunoglobulin Products, by Country USD Million (2025-2030)
  • Table 170. South America Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 171. South America Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 172. South America Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 173. South America Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 174. Brazil Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 175. Brazil Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 176. Brazil Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 177. Brazil Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 178. Argentina Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 179. Argentina Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 180. Argentina Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 181. Argentina Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 182. Rest of South America Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 183. Rest of South America Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 184. Rest of South America Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 185. Rest of South America Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 186. Asia Pacific Immunoglobulin Products, by Country USD Million (2025-2030)
  • Table 187. Asia Pacific Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 188. Asia Pacific Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 189. Asia Pacific Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 190. Asia Pacific Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 191. China Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 192. China Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 193. China Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 194. China Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 195. Japan Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 196. Japan Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 197. Japan Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 198. Japan Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 199. India Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 200. India Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 201. India Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 202. India Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 203. South Korea Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 204. South Korea Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 205. South Korea Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 206. South Korea Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 207. Taiwan Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 208. Taiwan Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 209. Taiwan Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 210. Taiwan Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 211. Australia Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 212. Australia Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 213. Australia Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 214. Australia Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 215. Rest of Asia-Pacific Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 216. Rest of Asia-Pacific Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 217. Rest of Asia-Pacific Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 218. Rest of Asia-Pacific Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 219. Europe Immunoglobulin Products, by Country USD Million (2025-2030)
  • Table 220. Europe Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 221. Europe Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 222. Europe Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 223. Europe Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 224. Germany Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 225. Germany Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 226. Germany Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 227. Germany Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 228. France Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 229. France Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 230. France Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 231. France Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 232. Italy Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 233. Italy Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 234. Italy Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 235. Italy Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 236. United Kingdom Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 237. United Kingdom Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 238. United Kingdom Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 239. United Kingdom Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 240. Netherlands Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 241. Netherlands Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 242. Netherlands Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 243. Netherlands Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 244. Rest of Europe Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 245. Rest of Europe Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 246. Rest of Europe Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 247. Rest of Europe Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 248. MEA Immunoglobulin Products, by Country USD Million (2025-2030)
  • Table 249. MEA Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 250. MEA Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 251. MEA Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 252. MEA Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 253. Middle East Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 254. Middle East Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 255. Middle East Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 256. Middle East Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 257. Africa Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 258. Africa Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 259. Africa Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 260. Africa Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 261. North America Immunoglobulin Products, by Country USD Million (2025-2030)
  • Table 262. North America Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 263. North America Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 264. North America Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 265. North America Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 266. United States Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 267. United States Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 268. United States Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 269. United States Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 270. Canada Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 271. Canada Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 272. Canada Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 273. Canada Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 274. Mexico Immunoglobulin Products, by Type USD Million (2025-2030)
  • Table 275. Mexico Immunoglobulin Products, by Application USD Million (2025-2030)
  • Table 276. Mexico Immunoglobulin Products, by Mode of Delivery USD Million (2025-2030)
  • Table 277. Mexico Immunoglobulin Products, by End User USD Million (2025-2030)
  • Table 278. Research Programs/Design for This Report
  • Table 279. Key Data Information from Secondary Sources
  • Table 280. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Immunoglobulin Products: by Type USD Million (2018-2023)
  • Figure 5. Global Immunoglobulin Products: by Application USD Million (2018-2023)
  • Figure 6. Global Immunoglobulin Products: by Mode of Delivery USD Million (2018-2023)
  • Figure 7. Global Immunoglobulin Products: by End User USD Million (2018-2023)
  • Figure 8. South America Immunoglobulin Products Share (%), by Country
  • Figure 9. Asia Pacific Immunoglobulin Products Share (%), by Country
  • Figure 10. Europe Immunoglobulin Products Share (%), by Country
  • Figure 11. MEA Immunoglobulin Products Share (%), by Country
  • Figure 12. North America Immunoglobulin Products Share (%), by Country
  • Figure 13. Global Immunoglobulin Products share by Players 2023 (%)
  • Figure 14. Global Immunoglobulin Products share by Players (Top 3) 2023(%)
  • Figure 15. Global Immunoglobulin Products share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Takeda Pharmaceutical Company (Japan) Revenue, Net Income and Gross profit
  • Figure 18. Takeda Pharmaceutical Company (Japan) Revenue: by Geography 2023
  • Figure 19. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 20. CSL Limited (Australia) Revenue: by Geography 2023
  • Figure 21. Grifols (Spain) Revenue, Net Income and Gross profit
  • Figure 22. Grifols (Spain) Revenue: by Geography 2023
  • Figure 23. Biotest Pharmaceuticals Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 24. Biotest Pharmaceuticals Corporation (United States) Revenue: by Geography 2023
  • Figure 25. Kedrion (Italy) Revenue, Net Income and Gross profit
  • Figure 26. Kedrion (Italy) Revenue: by Geography 2023
  • Figure 27. Octapharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Octapharma AG (Switzerland) Revenue: by Geography 2023
  • Figure 29. Abeona Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 30. Abeona Therapeutics (United States) Revenue: by Geography 2023
  • Figure 31. ADMA Biologics (United States) Revenue, Net Income and Gross profit
  • Figure 32. ADMA Biologics (United States) Revenue: by Geography 2023
  • Figure 33. Emergent Biosolutions. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Emergent Biosolutions. (United States) Revenue: by Geography 2023
  • Figure 35. Anthera Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 36. Anthera Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 37. Beijing Tiantan Biological Products (China) Revenue, Net Income and Gross profit
  • Figure 38. Beijing Tiantan Biological Products (China) Revenue: by Geography 2023
  • Figure 39. Global Immunoglobulin Products: by Type USD Million (2025-2030)
  • Figure 40. Global Immunoglobulin Products: by Application USD Million (2025-2030)
  • Figure 41. Global Immunoglobulin Products: by Mode of Delivery USD Million (2025-2030)
  • Figure 42. Global Immunoglobulin Products: by End User USD Million (2025-2030)
  • Figure 43. South America Immunoglobulin Products Share (%), by Country
  • Figure 44. Asia Pacific Immunoglobulin Products Share (%), by Country
  • Figure 45. Europe Immunoglobulin Products Share (%), by Country
  • Figure 46. MEA Immunoglobulin Products Share (%), by Country
  • Figure 47. North America Immunoglobulin Products Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Takeda Pharmaceutical Company (Japan)
  • CSL Limited (Australia)
  • Grifols (Spain)
  • Biotest Pharmaceuticals Corporation (United States)
  • Kedrion (Italy)
  • Octapharma AG (Switzerland)
  • Abeona Therapeutics (United States)
  • ADMA Biologics (United States)
  • Emergent Biosolutions. (United States)
  • Anthera Pharmaceuticals (United States)
  • Beijing Tiantan Biological Products (China)
Additional players considered in the study are as follows:
Bharat Serums and Vaccines (India) , Emergent Biosolutions (United States) , Gliknik (United States) , Hansamedical (Sweden) , Hualan Biological Engineering (China) , Immunomedics (United States) , Innate Pharma (France)
Select User Access Type

Key Highlights of Report


Mar 2024 245 Pages 85 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Immunoglobulin Products Market Quantitative research analysis
Global Immunoglobulin Products Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Immunoglobulin Products market are Takeda Pharmaceutical Company (Japan), CSL Limited (Australia), Grifols (Spain), Biotest Pharmaceuticals Corporation (United States), Kedrion (Italy), Octapharma AG (Switzerland), Abeona Therapeutics (United States), ADMA Biologics (United States), Emergent Biosolutions. (United States), Anthera Pharmaceuticals (United States) and Beijing Tiantan Biological Products (China).
In this highly competitive & fast evolving Immunoglobulin Products industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Hypogammaglobulinemia, Immunodeficiency Disease, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Multifocal Motor Neuropathy, Myasthenia Gravis, Specific Antibody Deficiency and Others are the potential customers of Immunoglobulin Products industry.
The Global Immunoglobulin Products market is expected to see a growth of 20.3% during projected year 2023 to 2030.

Know More About Global Immunoglobulin Products Market Report?

Have a Query? Click Here

Other Related Reports

Hyperphosphatemia Drugs Comprehensive Study by Type (Aluminum Phosphate Binder, Iron Phosphate Binder, Magnesium Phosphate Binder, Calcium Phosphate Binder), Application (Hospitals, Clinics, Others),...
$ 3650
Cancer CDK Inhibitors Comprehensive Study by Type (Ibrance (palbociclib), Kisqali (ribociclib), Verzenio (abemaciclib)), Application (Hospitals, Clinics, Other), Distribution Channel (Hospital Pharma...
$ 3350
Human Chorionic Gonadotropin Comprehensive Study by Technology (Natural Source Extraction, Recombinant Technology), End User (Fertility Clinics, Research Institutions, Others), Therapeutic Area (Fema...
$ 3450
Hib Vaccine Comprehensive Study by Type (Type 1-HIB Vaccine, Type 2- DTaP-IPV), Form (Liquid Monovalent HIB, Liquid Combination HIB, Lyophilized Monovalent HIB, Lyophilized Combination HIB), Age Grou...
$ 3750
Breast Cancer Predictive Genetic Testing Comprehensive Study by Type (High Penetrant Genes, Intermediate Penetrant Genes, Low Penetrant Genes), Application (Hospitals, Clinic Center, Pharmaceuticals,...
$ 3500
Adenovirus Vaccine Comprehensive Study by Type (Type 4 Vaccine, Type 7 Vaccine), Application (Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others) Players and Region - ...
$ 3500